1991 …2023
If you made any changes in Pure these will be visible here soon.

Personal profile

Clinical activities

Grigoriadis as the head of the myeloma service at Monash Health has been given the responsibility to expand the program and increase the profile as a clinical trials site. Prior to his commencement in that role in 2013 there were no myeloma studies at Monash Health; Grigoriadis has actively engaged with industry and been a PI on a total of 7 studies. Grigoriadis is currently a PI on 2 open Phase III myeloma studies including lenalidomide +/- pembrolizumab and pomalidomide +/- pembrolizumab in relapsed / refractory patients.

Community service

1. Leukaemia Foundation Patient Conference, Multiple Myeloma (2012, 2014, 2015)

2. Cancer Drugs Access Committee (2016-)

Research interests



Myeloid malignancies

Lymphoid malignancies




Supervision interests

Myeloma, MDS

Monash teaching commitment






  • Haematology
  • Myeloma
  • MDS
  • Immunology
  • NF-kappaB
  • Iron

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2023

Research Output 1991 2019

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Castillo, J. J., Guerrero-Garcia, T., Baldini, F., Tchernonog, E., Cartron, G., Ninkovic, S., Cwynarski, K., Dierickx, D., Tousseyn, T., Lansigan, F., Linnik, Y., Mogollon, R., Navarro, J. T., Olszewski, A. J., Reagan, J. L., Fedele, P., Gilbertson, M., Grigoriadis, G. & Bibas, M., 1 Feb 2019, In : British Journal of Haematology. 184, 4, p. 679-682 4 p.

Research output: Contribution to journalLetterOtherpeer-review

Open Access

Concentrating non-dilute urine before protein electrophoresis for the detection of monoclonal free light chains is unnecessary and wasteful

Haran, H., Choy, K. W., Wijeratne, N., Tudball, R., Doery, J., Grigoriadis, G. & Lu, Z., 1 Aug 2018, In : Pathology. 50, 5, p. 587-588 2 p.

Research output: Contribution to journalLetterOtherpeer-review

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

Yuen, H. L. A., Low, M. S. Y., Fedele, P., Kalff, A., Walker, P., Bergin, K., Coutsouvelis, J., Grigoriadis, G. & Spencer, A., 5 Apr 2018, (Accepted/In press) In : Leukemia and Lymphoma. 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma

Chee, A., Low, M. S., Vilcassim, S., Gregory, G. P., Gilbertson, M., Ratnasingam, S., Grigoriadis, G. & Fedele, P. L., Sep 2018, In : British Journal of Haematology. 182, 5, p. 739-741 3 p.

Research output: Contribution to journalArticleOtherpeer-review

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

Fedele, P. L., Willis, S. N., Liao, Y., Low, M. S., Rautela, J., Segal, D. H., Gong, J. N., Huntington, N. D., Shi, W., Huang, D. C. S., Grigoriadis, G., Tellier, J. & Nutt, S. L., 15 Nov 2018, In : Blood. 132, 20, p. 2166-2178 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access